Ginkgo Bioworks/DNA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatic testing products and services primarily provided to public health authorities. It also focuses on the design of next-generation cell therapies for autoimmune diseases. It uses its platform to develop and screen libraries of novel NK-specific and T-cell specific chimeric antigen receptor and switch receptor designs, which enable control and performance of immune cell-based therapies.

Ticker

DNA

Sector

Healthcare

Trading on

NYSE

Industry

Biotechnology & Drugs

CEO

Jason Kelly

Employees

1,218

Headquarters

Boston, United States

Ginkgo Bioworks Metrics

BasicAdvanced
$1.2B
Market cap
-
P/E ratio
-$0.43
EPS
-
Beta
-
Dividend rate
$1.2B
$2.55
$0.51
40M
5.342
-42.70%
-65.81%
-46.94%
5.6
1.089
1.356
-46.49%
57.62%
48.58%

What the Analysts think about Ginkgo Bioworks

Analyst Ratings

Majority rating from 7 analysts.
Sell

Ginkgo Bioworks Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-437.73% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$38M
9.22%
Net income
-$166M
-21.60%
Profit margin
-437.73%
-28.22%

Ginkgo Bioworks Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 4.00%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.09
-$0.16
-$0.11
-$0.08
-
Expected
-$0.08
-$0.09
-$0.10
-$0.08
-$0.08
Surprise
6.78%
86.67%
13.79%
-4.00%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Ginkgo Bioworks stock?

Ginkgo Bioworks (DNA) has a market cap of $1.2B as of June 18, 2024.

What is the P/E ratio for Ginkgo Bioworks stock?

The price to earnings (P/E) ratio for Ginkgo Bioworks (DNA) stock is 0 as of June 18, 2024.

Does Ginkgo Bioworks stock pay dividends?

No, Ginkgo Bioworks (DNA) stock does not pay dividends to its shareholders as of June 18, 2024.

When is the next Ginkgo Bioworks dividend payment date?

Ginkgo Bioworks (DNA) stock does not pay dividends to its shareholders.

What is the beta indicator for Ginkgo Bioworks?

Ginkgo Bioworks (DNA) does not currently have a Beta indicator.

What is the Ginkgo Bioworks stock price target?

The target price for Ginkgo Bioworks (DNA) stock is $1.43, which is NaN% below the current price of $. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Ginkgo Bioworks stock

Buy or sell Ginkgo Bioworks stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing